Manila Times Business
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received TzieldParis, June 13, 2026. The US Food and Drug Administration (FDA)
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000
1h ago
Ops+AI and Arrowhead Strategy Group Announce Strategic Partnership to Help Founders Build Smarter, Stronger, More Scalable Companies
2h ago
ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical
2h ago
HAMANASI ADVENTURE & DIVE RESORT, BELIZE RANKED #1 HOTEL IN CENTRAL AMERICA AND #15 IN THE WORLD IN 2026 TRIPADVISOR TRAVELERS’ CHOICE BEST OF THE BEST AWARDS
2h ago